QUIXIN SUMMARY
QUIXIN®
(levofloxacin ophthalmic solution) 0.5%
QUIXIN® (levofloxacin ophthalmic solution) 0.5% is a sterile topical ophthalmic solution. Levofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Levofloxacin is the pure (-)-( S)-enantiomer of the racemic drug substance, ofloxacin. It is more soluble in water at neutral pH than ofloxacin.
QUIXIN® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
AEROBIC GRAM-POSITIVE MICROORGANISMS
Corynebacterium species *
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Streptococcus
(Groups C/F)
Streptococcus
(Group G)
Viridans group streptococci
AEROBIC GRAM-NEGATIVE MICROORGANISMS
Acinetobacter Iwoffii *
Haemophilus influenzae
Serratia marcescens *
*Efficacy for this organism was studied in fewer than 10 infections.
|
NEWS HIGHLIGHTSMedia Articles Related to Quixin (Levofloxacin Ophthalmic)
Bacterial Conjunctivitis Drug Besivance Approved
Source: MedicineNet Pink Eye Specialty [2009.06.01]
Title: Bacterial Conjunctivitis Drug Besivance Approved
Category: Health News
Created: 6/1/2009
Last Editorial Review: 6/1/2009
Published Studies Related to Quixin (Levofloxacin Ophthalmic)
A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. [2009.07]
BACKGROUND: To determine the efficacy of conjunctival bacterial eradication following a 1-day, 3-day and 7-day application of topical 0.5% levofloxacin, with and without eyelid scrub, in patients with chronic blepharoconjunctivitis (CBC)... CONCLUSIONS: CBC eyes have a significantly higher number of positive cultures than eyes without CBC. The application of topical 0.5% levofloxacin for at least 3 days provided a significant reduction in the number of positive cultures as well as the number of bacteria harbored on the conjunctival surface.
Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. [2009.07]
BACKGROUND: The recommended second-line therapy for Helicobacter pylori (H. pylori) eradication is a quadruple regimen that fails in up to 30% of patients. Several recent studies suggest levofloxacin-based triple therapies as an alternative rescue treatment. However, dosage and length of levofloxacin-based regimens have not been established. AIM: To compare the efficacy and tolerability of four second-line levofloxacin-based schemes for H. pylori eradication... CONCLUSIONS: 10 days levofloxacin-based second-line regimens were effective in curing H. pylori infection in more than 85% of patients with a lower incidence of adverse effects in levofloxacin single-dosage scheme. The 10 days levofloxacin-based regimens were more effective than 7 days course of treatment showing that duration of therapy is the crucial factor affecting eradication rate.
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. [2009.05]
OBJECTIVES: This prospective study was designed to determine the efficacy of a levofloxacin-based rescue therapy for Helicobacter pylori infection after failure of standard triple therapies. We also surveyed the predictors of this rescue therapy... CONCLUSIONS: The EAL regimen can achieve an efficacy similar to that of the standard EBTM therapy. It may be very useful in countries where bismuth salts are not available. Compliance, CYP2C19 genotype and resistances to antibiotics may influence the outcome of levofloxacin-based rescue therapy. It seems advisable to reserve levofloxacin for rescue treatment to avoid an increase in the resistance phenomenon.
Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. [2009.04]
CONCLUSIONS: Based on the results, the formulations tested are bioequivalent.
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. [2009.04]
The aim of this study was to investigate the urinary bactericidal titers (UBTs) and 24-h area under the UBT-versus-time curve (AUBT) of intravenous doripenem (500 mg every 8 h [q8h]), a new carbapenem, versus those of intravenous levofloxacin (250 mg q24h) in patients with complicated urinary tract infections (cUTIs) or pyelonephritis...
Clinical Trials Related to Quixin (Levofloxacin Ophthalmic)
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis [Active, not recruiting]
The purpose of this study is to compare the safety and effectiveness of levofloxacin 750 mg
for 2 weeks or 750 mg for 3 weeks, compared to levofloxacin 500 mg for 4 weeks in the
treatment of chronic prostatitis.
A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects [Completed]
The primary objective of the study was to assess the bioequivalence of the oral suspension
formulation, the oral solution formulation, and the marketed tablet formulation of
levofloxacin, with the marketed tablet as the reference.
Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis [Completed]
The aim of the study is to evaluate the clinical and microbiological efficacies of three
times daily administration of levofloxacin 0,5% eye drops as compared to the more frequent
dosing (up to 8 times a day during the first 2 days and up to 4 times a day during the next
3 days) in patients with bacterial conjunctivitis.
Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections [Completed]
To compare the rates of clinical success of Topical Dermacyn™ vs. Oral Levofloxacin vs.
Combined therapy, in subjects with mild diabetic foot infections in non-ischemic ulcers.
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers [Completed]
224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78)
or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone
antibiotic.
|
